Heparin
- CAS No.
- 9005-49-6
- Chemical Name:
- Heparin
- Synonyms
- SODIUM HEPARIN;HEPARIN SODIUM SALT;Enoxaparine;PORCINE HEPARIN SODIUM;LOW MOLECULAR WEIGHT HEPARIN SODIUM;REVIPARIN SODIUM;clarin;pularin;HEPARIN;liquaemin
- CBNumber:
- CB6766085
- Molecular Formula:
- C26H41NO34S4
- Molecular Weight:
- 1134.93
- MDL Number:
- MFCD00131311
- MOL File:
- 9005-49-6.mol
| Melting point | 250 °C (decomp) |
|---|---|
| alpha | D20 +55° |
| storage temp. | Store at -20°C, sealed storage, protect from light |
| solubility | H2O: 50 mg/mL, clear, faintly yellow |
| form | crystalline (fine) |
| color | white |
| CAS DataBase Reference | 9005-49-6(CAS DataBase Reference) |
| EWG's Food Scores | 1 |
| NCI Dictionary of Cancer Terms | heparin |
| FDA UNII |
NADROPARIN (1K5KDI46KZ) REVIPARIN (5R0L1D739E) SEMULOPARIN (4QW4AN84NQ) TINZAPARIN (7UQ7X4Y489) ADOMIPARIN (9816XA9004) |
| NCI Drug Dictionary | Depo-Heparin |
| ATC code | B01AB01,B01AB51,C05BA03,C05BA53,S01XA14 |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|---|---|
| Signal word | Warning |
| Hazard statements | H302 |
| Precautionary statements | P264-P270-P301+P312-P330-P501 |
| Safety Statements | 24/25 |
| WGK Germany | 2 |
| RTECS | MI0850000 |
| F | 3-10 |
| Toxicity | LD50 oral in rat: 1950mg/kg |
Heparin price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Usbiological | 297177 | Heparin | 9005-49-6 | 100mg | $508 | 2021-12-16 | Buy |
| Usbiological | 517284 | Heparin | 9005-49-6 | 96Tests | $1083 | 2021-12-16 | Buy |
| Biosynth Carbosynth | YL30119 | Low calcium heparin | 9005-49-6 | 100mg | $342 | 2021-12-16 | Buy |
| Medical Isotopes, Inc. | 18620 | EnoxaparinSodium | 9005-49-6 | 5mg | $950 | 2021-12-16 | Buy |
Heparin Chemical Properties,Uses,Production
Description
Parnaparin sodium is a low molecular weight heparin obtained from bovine mucosal heparin by chemical depolymerization. It has more potent antithrombotic and profibrinolytic activity than heparin evidenced by its higher activity in inhibiting factor Xa and in reducing plasma activity of platelet activator inhibitor. It is effective in improving the venous blood outflow of lower limbs in deep vein thrombosis (DVT) patients in addition to preventing DVT following orthopaedic surgery, reportedly without causing bleeding complications. Parnaparin has also shown efficacy in inflammatory occlusive complications of postphlebitic syndrome and in acute myocardial infarction.
Chemical Properties
White or pale-colored amorphous powder; nearly odorless; hygroscopic. Soluble in water; insoluble in alcohol, benzene, acetone, chloroform, and ether; pH in 17% solution between 5.0 and 7.5.
Originator
Opocrin (Italy)
Occurrence
Heparin is a complex organic acid (mucopolysaccharide) present in mammalian tissues and a strong inhibitor of blood coagulation. Although the precise formula and structure of heparin are uncertain, it has been suggested that the formula for sodium heparinate, generally the form of the drug used in anticoagulant therapy, is (C12H16N2Na3)20 with a molecular weight of about 12,000. The commercial drug is derived from animal livers or lungs.
Uses
Medicine (anticoagulant), biochemical research, rodenticides.
Definition
heparin: A glycosaminoglycan (mucopolysaccharide)with anticoagulantproperties, occurring in vertebratetissues, especially the lungs andblood vessels.
Definition
A POLYSACCHARIDE that inhibits the formation of thrombin from prothrombin and thereby prevents the clotting of blood. It is used in medicine as an anticoagulant.
Definition
A complex organic acid (mucopolysaccharide) present in mammalian tissues; a strong inhibitor of blood coagulation; a dextrorotatory polysaccharide built up from hexosamine and hexuronic acid units containing sulfuric acid ester groups. Precise chemical fo
Manufacturing Process
5,000 pounds of beef intestine was introduced into a stainless steel reactor,
jacketed with thermostated water and steam. 200 gallons of water and 10
gallons of chloroform were added. The mixture was agitated, the temperature
was raised to 90°F and the agitation stopped. 5 gallons of toluene was added
and the vessel closed. Autolysis was continued for 17 hours.
The extractant solution, consisting of 30 gallons of glacial acetic acid, 35 gallons of 30% aqueous ammonia, 50% sodium hydroxide to adjust the pH to
9.6 at 80°F and water to make 300 gallons, was added to the tissue. With
agitation, the temperature was raised to 60°C and held there for 2 hours.
Then steam was applied and the temperature was raised to boiling. 200
pounds of coarse filter aid (perlite) was added and the mixture filtered
through a string discharge vacuum filter. The cake was washed with 200
gallons of hot water on the filter.
The filtrate was allowed to stand overnight and the fat skimmed off the top.
After cooling to 100°F, the filtrate was transferred to a tank with thermostated
water and the temperature set at 95° to 100°F. 24 gallons of pancreatic
extract, prepared as described above, was added in 4-gallon increments every
12 hours for 3 days. The batch was brought to a boil and cooled to room
temperature.
The batch was then filtered into a vessel and assayed for heparin content.
40,000,000 units were found in 1,000 gallons of filtrate. 20 kg of noctylamine was added and 105 pounds of glacial acetic acid was added to
bring the pH to 6.5. 20 gallons of methyl isobutyl ketone was added and the
whole mixture was vigorously agitated for 1 hour. The mixture was then
allowed to stand overnight. The clear, aqueous phase was drained off and
discarded. The grayish-brown interphase was then removed, together with a
small amount of the ketone phase, and transferred into a small kettle. The
interphase volume was 7 gallons.
30 gallons of methanol was added and the mixture warmed to 120°F and then
the pH was adjusted to 9.0. The mixture was then allowed to settle overnight.
The solids were collected with vacuum and washed with 5 gallons of
methanol. The cake was then suspended in 5 gallons of water and the heparin
precipitated with 10 gallons of methanol. The solids were collected under
vacuum. The dry weight of the cake was 1,000 grams and the total units were
38,000,000, according to US Patent 2,884,358.
brand name
Liquaemin Sodium (Organon); Panheprin (Hospira);Fluxum.
Therapeutic Function
Anticoagulant
Biological Functions
Heparin (heparin sodium) is a mixture of highly electronegative acidic mucopolysaccharides that contain numerous N- and O-sulfate linkages. It is produced by and can be released from mast cells and is abundant in liver, lungs, and intestines.
Hazard
May cause internal bleeding.
Mechanism of action
The anticoagulation action of heparin depends on
the presence of a specific serine protease inhibitor (serpin)
of thrombin, antithrombin III, in normal blood.
Heparin binds to antithrombin III and induces a conformational
change that accelerates the interaction of
antithrombin III with the coagulation factors. Heparin
also catalyzes the inhibition of thrombin by heparin cofactor
II, a circulating inhibitor. Smaller amounts of
heparin are needed to prevent the formation of free
thrombin than are needed to inhibit the protease activity
of clot-bound thrombin. Inhibition of free thrombin
is the basis of low-dose prophylactic therapy.
Pharmacokinetics
The pharmacokinetic profiles of heparin and LMWHs are quite different. Whereas heparin is only 30% absorbed following subcutaneous injection, 90% of LMWH is systemically absorbed. The binding affinity of heparin to various protein receptors, such as those on plasma proteins, endothelial cells, platelets, platelet factor 4 (PF4), and macrophages, is very high and is related to the high negative-charged density of heparin. This high nonspecific binding decreases bioavailability and patient variability. Additionally, heparin's nonspecific binding may account for heparin's narrow therapeutic window and heparin-induced thrombocytopenia (HIT), a major limitation of heparin. These same affinities are quite low, however, in the case of LMWHs. These parameters explain several of the benefits of the LMWH's. The favorable absorption kinetics and low protein binding affinity of the LMWHs results in a greater bioavailability compared with heparin. The lowered affinity of LMWHs for PF4 seems to correlate with a reduced incidence of HIT. Heparin is subject to fast zero-order metabolism in the liver, followed by slower first-order clearance from the kidneys. The LMWHs are renally cleared and follow first-order kinetics. This makes the clearance of LMWHs more predictable as well as resulting in a prolonged half-life. Finally, the incidence of heparin-mediated osteoporosis is significantly diminished with use of LMWHs as opposed to heparin.
Pharmacology
The physiological function of heparin is not completely
understood. It is found only in trace amounts in
normal circulating blood. It exerts an antilipemic effect
by releasing lipoprotein lipase from endothelial cells;
heparinlike proteoglycans produced by endothelial
cells have anticoagulant activity. Heparin decreases
platelet and inflammatory cell adhesiveness to endothelial
cells, reduces the release of platelet-derived growth
factor, inhibits tumor cell metastasis, and exerts an antiproliferative
effect on several types of smooth muscle.
Therapy with heparin occurs in an inpatient setting.
Heparin inhibits both in vitro and in vivo clotting of
blood. Whole blood clotting time and activated partial
thromboplastin time (aPTT) are prolonged in proportion
to blood heparin concentrations.
Side effects
The major adverse reaction resulting from heparin therapy is hemorrhage. Bleeding can occur in the urinary or gastrointestinal tract and in the adrenal gland. Subdural hematoma, acute hemorrhagic pancreatitis, hemarthrosis, and wound ecchymosis also occur. The incidence of life-threatening hemorrhage is low but variable. Heparin-induced thrombocytopenia of immediate and delayed onset may occur in 3 to 30% of patients. The immediate type is transient and may not involve platelet destruction, while the delayed reaction involves the production of heparin-dependent antiplatelet antibodies and the clearance of platelets from the blood. Heparin-associated thrombocytopenia may be associated with irreversible aggregation of platelets (white clot syndrome). Additional untoward effects of heparin treatment include hypersensitivity reactions (e.g., rash, urticaria, pruritus), fever, alopecia, hypoaldosteronism, osteoporosis, and osteoalgia.
Drug interactions
Potentially hazardous interactions with other drugs
Analgesics: increased risk of bleeding with NSAIDs
- avoid concomitant use with IV diclofenac;
increased risk of haemorrhage with ketorolac -
avoid.
Nitrates: anticoagulant effect reduced by infusions of
glyceryl trinitrate.
Use with care in patients receiving oral
anticoagulants, platelet aggregation inhibitors, aspirin
or dextran.
Metabolism
Heparin is prescribed on a unit (IU) rather than milligram
basis. The dose must be determined on an individual
basis. Heparin is not absorbed after oral administration
and therefore must be given parenterally.
Intravenous administration results in an almost immediate
anticoagulant effect. There is an approximate 2-hour
delay in onset of drug action after subcutaneous administration.
Intramuscular injection of heparin is to be
avoided because of unpredictable absorption rates, local
bleeding, and irritation. Heparin is not bound to
plasma proteins or secreted into breast milk, and it does
not cross the placenta.
Heparin’s action is terminated by uptake and metabolism
by the reticuloendothelial system and liver and
by renal excretion of the unchanged drug and its depolymerized
and desulfated metabolite. The relative
proportion of administered drug that is excreted as unchanged
heparin increases as the dose increases. Renal
insufficiency reduces the rate of heparin clearance from
the blood.
Purification Methods
Most likely contaminants are mucopolysaccharides including heparin sulfate and dermatan sulfate. Purify heparin by precipitation with cetylpyridinium chloride from saturated solutions of high ionic strength. [Cifonelli & Roden Biochemical Preparations 12 12 1968, Wolfrom et al. J Org Chem 29 540 1946, Huggard Adv Carbohydr Chem 10 336-368 1955]
Heparin Preparation Products And Raw materials
Raw materials
1of2
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Hebei Mojin Biotechnology Co., Ltd | +8613288715578 | sales@hbmojin.com | China | 12456 | 58 |
| Hebei Yanxi Chemical Co., Ltd. | +8617531190177 | peter@yan-xi.com | China | 5993 | 58 |
| Henan Tianfu Chemical Co.,Ltd. | +86-0371-55170693 +86-19937530512 | info@tianfuchem.com | China | 21691 | 55 |
| Hebei Guanlang Biotechnology Co., Ltd. | +86-19930503282 | alice@crovellbio.com | China | 8823 | 58 |
| BOC Sciences | +1-631-485-4226 | inquiry@bocsci.com | United States | 19553 | 58 |
| CONIER CHEM AND PHARMA LIMITED | +8618523575427 | sales@conier.com | China | 49390 | 58 |
| career henan chemical co | +86-0371-86658258 15093356674; | factory@coreychem.com | China | 29826 | 58 |
| Neostar United (Changzhou) Industrial Co., Ltd. | +86-519-519-85557386 | marketing1@neostarunited.com | China | 8349 | 58 |
| TargetMol Chemicals Inc. | +1-781-999-5354 +1-00000000000 | marketing@targetmol.com | United States | 19892 | 58 |
| Hefei TNJ Chemical Industry Co.,Ltd. | 0551-65418671 | sales@tnjchem.com | China | 34572 | 58 |
View Lastest Price from Heparin manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2023-11-24 | Heparin
9005-49-6
|
US $20.00-10.00 / kg | 1kg | 0.99 | 5 tons | Hebei Yanxi Chemical Co., Ltd. | |
 |
2023-09-01 | Heparin
9005-49-6
|
US $0.00 / KG | 1KG | 99% | 50000KG/month | Hebei Mojin Biotechnology Co., Ltd | |
 |
2023-03-06 | Enoxaparin Sodium
9005-49-6
|
US $10.70 / Kg/Bag | 10g | 99% | 10000kg | Hebei Guanlang Biotechnology Co,.LTD |
-
- Heparin
9005-49-6
- US $20.00-10.00 / kg
- 0.99
- Hebei Yanxi Chemical Co., Ltd.
-
- Heparin
9005-49-6
- US $0.00 / KG
- 99%
- Hebei Mojin Biotechnology Co., Ltd
-
- Enoxaparin Sodium
9005-49-6
- US $10.70 / Kg/Bag
- 99%
- Hebei Guanlang Biotechnology Co,.LTD
9005-49-6(Heparin)Related Search:
1of4